Product Description
Atorvastatin is used together with diet, weight loss, and exercise to reduce the risk of heart attack and stroke and to decrease the chance that heart surgery will be needed in people who have heart disease or who are at risk of developing heart disease. Atorvastatin is also used to decrease the amount of fatty substances such as low-density lipoprotein (LDL) cholesterol ('bad cholesterol') and triglycerides in the blood and to increase the amount of high-density lipoprotein (HDL) cholesterol ('good cholesterol') in the blood.
Mechanisms of Action: HMG-CoA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, China, Denmark, Estonia, Finland, Korea, Norway, United States
Active Clinical Trial Count: 24
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Pain|Breast Cancer|Dyslipidemia|Hypercholesterolemia|Hypertension|Obesity|Post Acute COVID-19 Syndrome|Prostate Cancer
Phase 2: Kidney Cancer|Ovarian Cancer
Phase 1: Conduct Disorder|General Diabetes|Healthy Volunteers|Hyperlipidemia|Overweight|Pregnancy Outcomes|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| IMPACT-LC | P3 |
Not yet recruiting |
Post Acute COVID-19 Syndrome |
2026-02-01 |
2025-05-16 |
Primary Endpoints|Treatments |
|
| 2019-001982-34 | P2 |
Active, not recruiting |
Kidney Cancer|Ovarian Cancer|Prostate Cancer|Breast Cancer |
2025-06-15 |
|||
| HRS9531-107 | P1 |
Active, not recruiting |
Type 2 Diabetes |
2025-05-01 |
69% |
2025-01-08 |
Primary Endpoints|Start Date|Treatments|Trial Status |
| C3421086 | P1 |
Completed |
Obesity|Overweight |
2025-04-14 |
69% |
2025-05-28 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| BR-FAEC-CT-301 | P3 |
Completed |
Hypertension|Hypercholesterolemia |
2024-09-05 |
7% |
2024-10-19 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| NCT05342974 | P1 |
Completed |
Pregnancy Outcomes |
2023-12-31 |
2025-03-22 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
| DW1125-301 | P3 |
Completed |
Dyslipidemia|Hypercholesterolemia |
2023-04-13 |
2023-08-02 |
||
| BCHCP | P3 |
Not yet recruiting |
Obesity|Acute Pain |
2021-10-31 |
|||
| 2024-515404-39-00 | P3 |
Active, not recruiting |
Breast Cancer |
2045-01-01 |
2025-05-02 |
Treatments |
|
| ESTO2 | P3 |
Recruiting |
Prostate Cancer |
2025-12-31 |
2022-10-22 |
Primary Endpoints|Start Date|Treatments |
|
| PSM1A | P1 |
Not yet recruiting |
Healthy Volunteers |
2025-12-01 |
23% |
2023-11-19 |
Primary Endpoints|Treatments |
| D7260C00017 | P1 |
Recruiting |
Type 2 Diabetes|Obesity |
2025-10-15 |
69% |
2025-05-16 |
Primary Endpoints|Start Date |
| HDM1002-106 | P1 |
Not yet recruiting |
Overweight |
2025-02-01 |
2% |
2024-09-24 |
Primary Endpoints |
| NN9838-4694 | P1 |
Completed |
Obesity |
2024-10-16 |
12% |
2025-01-11 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Trial Status |
| EC0007 | P1 |
Completed |
Type 2 Diabetes |
2024-04-15 |
12% |
2024-07-23 |
|
| MK-0616-024 | P1 |
Completed |
Healthy Volunteers |
2023-12-29 |
2024-11-22 |
Primary Endpoints|Treatments |
|
| CTR20233333 | P1 |
Completed |
Hypercholesterolemia |
2023-12-27 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| TA-8995-11 | P1 |
Completed |
Healthy Volunteers |
2023-12-02 |
69% |
2025-02-07 |
Primary Endpoints|Treatments |
| CIBI362D101 | P1 |
Completed |
Overweight |
2023-08-18 |
4% |
2024-06-28 |
Primary Endpoints|Treatments |
| CTR20243779 | P1 |
Active, not recruiting |
Overweight |
None |
2025-06-01 |
Start Date|Treatments|Trial Status |
|
| CTR20180617 | P1 |
Active, not recruiting |
Hyperlipidemia |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
| ACTRN12618000208202 | P1 |
Not yet recruiting |
Conduct Disorder |
None |
2024-08-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
| CTR20244613 | P1 |
Active, not recruiting |
Healthy Volunteers|General Diabetes |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
| CTR20251534 | P1 |
Active, not recruiting |
Hypercholesterolemia|Hyperlipidemia |
None |
2025-05-25 |
Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/09/2025 |
News Article |
NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial |
|
06/05/2025 |
News Article |
NewAmsterdam Pharma to Host R&D Day on June 11, 2025 |
|
05/14/2025 |
News Article |
Duro Launches Technology Partner Program to Deliver Complete Digital Thread for Hardware Engineering |
|
05/13/2025 |
News Article |
NATIONAL GEOGRAPHIC-LINDBLAD EXPEDITIONS UNVEILS FIRST-EVER EUROPEAN RIVER EXPEDITION SEASON ON THE RHINE |